• Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis. 

  Goldman, NR; Nihtyanova, SI; Beesley, CF; Wells, AU; Denton, CP; Renzoni, EA; Mageed, R; Ong, VH (Oxford University Press, 2025-01-03)

  OBJECTIVES: Systemic sclerosis (SSc)-interstitial lung disease (ILD) is one of the leading causes of mortality in SSc. Data from randomised controlled trials (RCTs) supports rituximab and tocilizumab monotherapy but there ...

• Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome 

  Bombardieri, M (BMJ Publishing Group, 2022-04-07)

• THE SJOGREN'S TOOL FOR ASSESSING RESPONSE (STAR): ASSESSMENT OF RESPONSE RATES OVERALL, ACCORDING TO BASELINE ACTIVITY AND BY DOMAIN: REANALYSIS OF 9 CLINICAL TRIALS IN PRIMARY SJOGREN'S SYNDROME 

  Seror, R; Baron, G; Cornec, D; Perrodeau, E; Camus, M; Bowman, SJ; Bombardieri, M; Bootsma, H; Arends, S; Gottenberg, JE (2022)

• TRPC1 links calcium signaling to cellular senescence in the protection against post-traumatic osteoarthritis 

  Sambale, M; Lively, S; Espin-Garcia, O; Potla, P; Pastrello, C; Bödecker, S; Wessendorf, L; Kleimann, S; Paruzel, P; Asgarian, R (American Society for Clinical Investigation, 2024-12-24)

  Transient receptor potential channel 1 (TRPC1) is a widely expressed mechanosensitive ion channel located within the endoplasmic reticulum membrane, crucial for refilling depleted internal calcium stores during activation ...

• Tissue-specific enhancer-gene maps from multimodal single-cell data identify causal disease alleles. 

  Sakaue, S; Weinand, K; Isaac, S; Dey, KK; Jagadeesh, K; Kanai, M; Watts, GFM; Zhu, Z; Accelerating Medicines Partnership® RA/SLE Program and Network; Brenner, MB (2024-04)

  Translating genome-wide association study (GWAS) loci into causal variants and genes requires accurate cell-type-specific enhancer-gene maps from disease-relevant tissues. Building enhancer-gene maps is essential but ...

• The influence of deprivation in the outcomes of psoriatic arthritis within the UK-utilizing Outcomes of Treatment in Psoriatic Arthritis Study Syndicate (OUTPASS) data. 

  Lyon, M; Zhao, SS; Jani, M; Chinoy, H; Barton, A; Bluett, J; OUTPASS Study Syndicate (2024)

• The chromatin landscape of pathogenic transcriptional cell states in rheumatoid arthritis. 

  Weinand, K; Sakaue, S; Nathan, A; Jonsson, AH; Zhang, F; Watts, GFM; Al Suqri, M; Zhu, Z; Accelerating Medicines Partnership Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Network; Rao, DA (2024-05-31)

  Synovial tissue inflammation is a hallmark of rheumatoid arthritis (RA). Recent work has identified prominent pathogenic cell states in inflamed RA synovial tissue, such as T peripheral helper cells; however, the epigenetic ...

• Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus. 

  Ruscitti, P; Allanore, Y; Baldini, C; Barilaro, G; Bartoloni Bocci, E; Bearzi, P; Bellis, E; Berardicurti, O; Biaggi, A; Bombardieri, M (2024)

  Inflammatory rheumatic diseases are different pathologic conditions associated with a deregulated immune response, codified along a spectrum of disorders, with autoinflammatory and autoimmune diseases as two-end phenotypes ...

• Protocol for differentiation of monocytes and macrophages from human induced pluripotent stem cells. 

  Emmerich, K; Calcaterra, F; Tang, X; Chen, G; Pontarini, E; Ciceri, R; Yang, D; Joseph, B; Della Bella, S; Varea, I (2024-07-27)

  Study of disease-relevant immune cells, namely monocytes and macrophages, is limited based on availability of primary tissue, a limitation that can be remedied using human induced pluripotent stem cell (hiPSC) technology. ...

• Precision medicine in Sjögren's disease. 

  Gandolfo, S; Bombardieri, M; Pers, J-O; Mariette, X; Ciccia, F (2024-09)

  Sjögren's disease is a clinically and pathophysiologically heterogeneous disease to which precision medicine, on the basis of clinical and biological heterogeneity, has been not always applicable. In patients with Sjögren's ...

• Patient stratification using plasma cytokines and their regulators in sepsis: relationship to outcomes, treatment effect and leucocyte transcriptomic subphenotypes. 

  Antcliffe, DB; Mi, Y; Santhakumaran, S; Burnham, KL; Prevost, AT; Ward, JK; Marshall, TJ; Bradley, C; Al-Beidh, F; Hutton, P (2024-05-20)

  RATIONALE: Heterogeneity of the host response within sepsis, acute respiratory distress syndrome (ARDS) and more widely critical illness, limits discovery and targeting of immunomodulatory therapies. Clustering approaches ...

• P154 Male lupus characteristics from multi-ethnic cohort 

  Aldeyarbi, H; George, S; Marchan, G; Rajakariar, R; Cove-Smith, A; Pakozdi, A; Cunningham, M; Lewis, M; Turner, B; Pyne, D (Oxford University Press (OUP), 2024-04-24)

• Novel therapies for cancer-induced bone pain 

  Haroun, R; Gossage, SJ; Iseppon, F; Fudge, A; Caxaria, S; Arcangeletti, M; Leese, C; Davletov, B; Cox, JJ; Sikandar, S (2024-07-01)

  Cancer pain is a growing problem, especially with the substantial increase in cancer survival. Reports indicate that bone metastasis, whose primary symptom is bone pain, occurs in 65–75% of patients with advanced breast ...

• Loss of synovial tissue macrophage homeostasis precedes rheumatoid arthritis clinical onset 

  Hanlon, MM; Smith, CM; Canavan, M; Neto, NGB; Song, Q; Lewis, MJ; O'Rourke, AM; Tynan, O; Barker, BE; Gallagher, P (2024-09-27)

  This study performed an in-depth investigation into the myeloid cellular landscape in the synovium of patients with rheumatoid arthritis (RA), "individuals at risk" of RA, and healthy controls (HC). Flow cytometric analysis ...

• Diminished expression of the ubiquitin-proteasome system in early treatment-naïve patients with rheumatoid arthritis and concomitant type 2 diabetes may be linked to IL-1 pathway hyper-activity; results from PEAC cohort 

  Ruscitti, P; Currado, D; Rivellese, F; Vomero, M; Navarini, L; Cipriani, P; Pitzalis, C; Giacomelli, R (2024-09-28)

  OBJECTIVE: Based on the recent evidence of IL-1 inhibition in patients with rheumatoid arthritis (RA) and concomitant type 2 diabetes (T2D), we evaluated the synovial tissue expression of IL-1 related genes in relationship ...

• Associations Between Rheumatoid Arthritis Clinical Factors and Synovial Cell Types and States. 

  Weisenfeld, D; Zhang, F; Donlin, L; Jonsson, AH; Apruzzese, W; Campbell, D; Accelerating Medicines Partnership Program: RA/SLE Network; Rao, DA; Wei, K; Holers, VM (2024-03)

  OBJECTIVE: Recent studies have uncovered diverse cell types and states in the rheumatoid arthritis (RA) synovium; however, limited data exist correlating these findings with patient-level clinical information. Using the ...

• 754 Sex Differences in a Murine Model of Osteoarthritis 

  Bharde, S; Caxaria, S; Celik, P; Srithasan, A; Fuller, A; Sikandar, S (Elsevier, 2024-04)

• 645 FUNCTIONAL INTERACTION OF CXCR2 AND β1-INTEGRIN SIGNALING IN THE REGULATION OF CARTILAGE HOMEOSTASIS 

  Asgarian, R; Schäfer, A; Gronewold, R; Dell'Accio, F; Pap, T; Sherwood, J (Elsevier, 2024-04)

• 069 INTRA-ARTICULAR ADMINISTRATION OF AGRIN INDUCES RAPID AND SUSTAINED PAIN RELIEF IN OSTEOARTHRITIS 

  Dajas-Bailador, F; Chapman, V; Lucci, C; Rathbone, A; Bharde, S; Sikandar, S; Dell'Accio, F; Eldridge, S (Elsevier, 2024-04)

• Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells in lupus. 

  Law, C; Wacleche, VS; Cao, Y; Pillai, A; Sowerby, J; Hancock, B; Horisberger, A; Bracero, S; Skidanova, V; Li, Z (2024-07)

  Systemic lupus erythematosus (SLE) is prototypical autoimmune disease driven by pathological T cell-B cell interactions1,2. Expansion of T follicular helper (TFH) and T peripheral helper (TPH) cells, two T cell populations ...

View more